Terra Firma Energy Highlights the Critical Role of Flexible Generation in Securing the UK Power System January 8, 2026 Terra Firma Energy today reaffirmed the essential role that flexible generation plays in maintaining the stability, resilience, and affordability of the UK electricity system as renewable penetration continues to accelerate. Recent industry analysis and project developments across the UK energy sector underline a growing consensus: as nuclear capacity remains constrained, fast-responding flexible generation is indispensable [...]
OneSource Virtual Announces Strategic, Majority Growth Investment from TA January 7, 2026 OneSource Virtual (OSV), a leading provider of HR and payments services for the Workday ecosystem, today announced a strategic, majority growth investment from TA Associates (TA), a leading global private equity firm. This investment will support the continuation of OSV’s organic growth, product innovation, and enhanced customer capabilities across the Workday ecosystem. This press release [...]
Loomis Sayles Proudly Celebrates 100 Years of Client Commitment and Investment Excellence January 6, 2026 Loomis, Sayles & Company, the investment manager with $425 billion in assets under managementi, proudly marks its centennial year, celebrating a legacy of independent thinking and a relentless commitment to helping clients achieve their goals. Founded in January 1926, Loomis Sayles has grown to serving over 1,000 institutional clients in 28 countries offering differentiated investment [...]
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq January 5, 2026 Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
Prometheus Group Expands Commitment to Environmental Health and Safety with NiSoft Acquisition December 23, 2025 Combines Best-in-Class Digital Permitting and Safety Solutions for Asset-Intensive Industries
Kolibri Global Energy Inc. Provides Operations Update December 22, 2025 Kolibri Global Energy Inc. (the “Company” or “Kolibri”) (TSX: KEI, NASDAQ: KGEI) is pleased to provide an operations update on its latest wells in its Tishomingo field in Oklahoma. FIELD UPDATE The field, with the addition of the new Barnes and Velin wells, is currently producing over 6,000 Barrels of oil equivalent per day (“BOEPD”). [...]
Strada Closes 2025 With Major Growth Milestones, a Strengthened Leadership Team and a Bold Vision for Innovation December 19, 2025 Strada, a people, payroll and technology leader that simplifies international workforce management, today celebrates a series of major achievements that made 2025 a defining year for the organization. Following its divestiture in 2024, Strada closes 2025 as a fully independent business with momentum and a clear path into 2026. As Strada moved through its first [...]
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP) December 19, 2025 EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this [...]
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector December 18, 2025 SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1 The new autoinjector option increases convenience, enhances individual patient experience and expands administration options
Orbia Fluor & Energy Materials Completes Expansion of Custom Electrolyte Facility December 16, 2025 Orbia Advance Corporation S.A.B. de C.V. (BMV: ORBIA*) Fluor & Energy Materials business today announced it has completed the expansion of its Custom Electrolyte facility for lithium-ion and other battery chemistries in Madison, Wisconsin, increasing the site production capacity by roughly 300%. The second and final phase for the expansion was completed in early December [...]